advertisement
Sun X 11
Showing records 1 to 11 | Display all abstracts from Sun X71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Sun J
ACS applied materials & interfaces 2017; 9: 7990-7999
71181 The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study
Li S; Shao M
Oncotarget 2017; 8: 2816-2824
71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Lei Y
ACS applied materials & interfaces 2017; 9: 7990-7999
71181 The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study
Tang B
Oncotarget 2017; 8: 2816-2824
71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Dai Z
ACS applied materials & interfaces 2017; 9: 7990-7999
71181 The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study
Zhang A
Oncotarget 2017; 8: 2816-2824
71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Liu X
ACS applied materials & interfaces 2017; 9: 7990-7999
71181 The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study
Cao W
Oncotarget 2017; 8: 2816-2824
71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Huang T
ACS applied materials & interfaces 2017; 9: 7990-7999
71181 The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study
Sun X
Oncotarget 2017; 8: 2816-2824
71498 Sustained Release of Brimonidine from a New Composite Drug Delivery System for Treatment of Glaucoma
Wu J; Xu ZP; Sun X
ACS applied materials & interfaces 2017; 9: 7990-7999
